Faeth Therapeutics (FTH) Accumulated Depreciation (2020 - 2026)

Faeth Therapeutics (FTH) has reported Accumulated Depreciation for 7 consecutive years, with $606000.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Accumulated Depreciation rose 26.25% year-over-year to $606000.0; the trailing twelve-month figure through Jun 2026 stood at $606000.0 (up 26.25% YoY), and the FY2025 full-year result was $540000.0, down 63.9% from the prior year.
• Accumulated Depreciation rose to $606000.0 in Q2 2026 per FTH's latest filing, from $581000.0 in the prior quarter.
• Across five years, Accumulated Depreciation topped out at $2.1 million in Q3 2024 and bottomed at $448000.0 in Q1 2025.
• Historically, Accumulated Depreciation has averaged $1.3 million across 5 years, with a median of $1.5 million in 2022.
• The sharpest annual moves came in 2022 and 2025: Accumulated Depreciation soared 100.27% in 2022, then sank 76.16% in 2025.
• Over 5 years, Accumulated Depreciation stood at $1.4 million in 2022, then increased by 19.68% to $1.7 million in 2023, then retreated by 13.38% to $1.5 million in 2024, then slumped by 63.9% to $540000.0 in 2025, then gained by 12.22% to $606000.0 in 2026.
• According to Business Quant data, Accumulated Depreciation over the past three periods registered $606000.0, $581000.0, and $540000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.